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Abstract
Objectives
To determine whether the interleukin-33 (IL-33)-interleukin-1 receptor like 1 (IL-1RL1) sig-
naling pathway is implicated in the risk of subclinical atherosclerosis in patients with rheu-
matoid arthritis (RA).
Methods
A total of 576 Spanish RA patients from Northern Spain were genotyped for 6 well-known
IL33-IL1RL1 polymorphisms (IL33 rs3939286, IL33 rs7025417, IL33 rs7044343, IL1RL1
rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714) by TaqMan genotyping assay. The
presence of subclinical atherosclerosis was determined by the assessment of carotid
intima-media thickness (cIMT) by carotid ultrasound (US).
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Results
RA patients carrying the TT genotype of the IL33 rs3939286 polymorphism had lower cIMT
values than those homozygous for the CC genotype (mean ± standard deviation (SD): 0.71
± 0.14 mm versus 0.76 ± 0.16 mm, respectively) while patients carrying the CT genotype
had intermediate cIMT values (mean ± SD: 0.73 ± 0.17 mm). Moreover, RA patients carry-
ing the mutant allele T of the IL33 rs3939286 polymorphism exhibited significantly lower
cIMT values than those carrying the wild allele C (mean ± SD: 0.72 ± 0.16 mm versus 0.75 ±
0.18 mm respectively; p = 0.04). The association of both genotype and allele frequencies of
IL33 rs3939286 and cIMT levels remained statistically significant after adjustment for sex,
age at the time of US study, follow-up and center (p = 0.006 and p = 0.0023, respectively),
evidencing that the potential effect conferred by IL33 rs3939286 may be independent of
confounder factors. No association with other IL33-IL1RL1 genetic variants was observed.
Conclusions
In conclusion, our results may suggest a potential protective effect of the IL33 rs3939286
allele T in the risk of subclinical atherosclerosis in patients with RA.
Introduction
Rheumatoid arthritis (RA) is a complex autoimmune disease associated with progressive dis-
ability, systemic complications and early death [1]. Mortality is higher among RA patients than
in the general population, and cardiovascular (CV) complications remain a major challenge
[2]. The mechanisms leading to accelerated atherosclerosis in RA are complex, including not
only the effect of traditional CV risk factors and chronic inflammation [2–3]. In this regard,
several pieces of evidence indicate that genetic polymorphisms located inside and outside of
the human leukocyte antigen (HLA) region also influence the risk of CV disease in RA [2,4–5].
Subclinical atherosclerosis has been observed in RA patients, even in those without traditional
CV risk factors, and abnormally high values of carotid intima-media thickness (cIMT) have
been found to predict the risk of CV events in these patients [6].
Interleukin-33 (IL-33) is a newly characterized cytokine that belongs to the IL-1 family [7].
This cytokine is constitutively expressed by tissue barrier cells (such as the epithelial and endo-
thelial cells of many organs), but it is also expressed by some innate immune cells (such as mac-
rophages and dendritic cells). IL-33 displays both nuclear and extracellular effects and
mediates its biological function by interacting with its receptor (IL-1 receptor like 1 (IL-1RL1)
also called ST2) and coreceptor (IL-1 receptor accessory protein (IL-1RAcP)). Since this bind-
ing exerts relevant immunomodulatory functions producing chemokines and pro-inflamma-
tory and Th2-associated cytokines [7], IL-33-IL-1RL1 has been considered as a key pathway
involved in inflammatory diseases. In accordance with that, a pathogenic role of IL-33 has been
found in RA, where its levels are significantly elevated both in synovial fluid and serum [8].
Moreover, a relationship between baseline detectable IL-33 concentrations and the develop-
ment of severe subclinical atherosclerosis in patients diagnosed with RA has been described
[9].
Regarding genetic studies, polymorphisms located both in IL33 and IL1RL1 have been asso-
ciated with autoimmunity. An association between IL33 rs3939286 and some immune-medi-
ated diseases such as inflammatory bowel disease (IBD) has been described [10]. Additionally,
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IL33 rs7025417 and IL33 rs4742170, which is in high linkage disequilibrium with IL33
rs7025417, have been related to coronary artery disease (CAD) and ischemic stroke in non-
rheumatic Chinese individuals, respectively [11,12]. Also in the Chinese population, the IL33
rs7044343 polymorphism has been associated with RA [13]. Regarding IL1RL1, a relevant role
of IL1RL1 rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714 in the development of several
inflammatory conditions such as IBD and ankylosing spondylitis has been proposed [10,14].
Taking into account all these considerations, in the present study we aimed to determine,
for the first time, whether 6 genetic variants at IL33 and IL1RL1, previously associated with
immune-mediated diseases, are involved in the risk of subclinical atherosclerosis in Spanish
patients with RA.
Patients and Methods
2.1. Patients and Study Protocol
A set of 576 Spanish patients with RA were included in the present study. Blood samples were
obtained from patients recruited from Hospital Lucus Augusti (Lugo) and Hospital Marqués
de Valdecilla (Santander) in Northern Spain. A subject’s written consent was obtained accord-
ing to the declaration of Helsinki, and the study was approved by the Ethics Committees of
clinical research of Galicia (CAEI) for Hospital Lucus Augusti in Lugo and Cantabria (CEIC)
for Hospital Universitario Marqués de Valdecilla in Santander.
All the patients fulfilled the 2010 classification criteria for RA [15]. In all the cases, patients
were assessed for 3 polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and 3
genetic variants located within IL1RL1 (rs2058660, rs2310173, rs13015714). Also, cIMT was
determined by carotid ultrasound (US) technology. Information on the main demographic
data, clinical characteristics, CV risk factors and CV events of the patients enrolled in the study
is shown in Table 1. Definitions of CV events (ischemic heart disease, heart failure, cerebrovas-
cular accident or peripheral arteriopathy) and those for traditional CV risk factors were estab-
lished as previously described [2, 6].
2.2. Genotyping
Genomic deoxyribonucleic acid (DNA) from all patients was extracted from peripheral white
blood cells using standard procedures.
The selection of single-nucleotide polymorphisms (SNPs) was based on their position with
regards to the IL33-IL1RL1 region and their previously reported associations with several
inflammatory diseases. Following these criteria, we performed a tagging using data from Hap-
Map project (http://www.hapmap.org) and Haploview software version 4.2 and considering
r2>0.8, haplotype frequency>5%, minor allele frequency>10%) (data in S1 and S2 figs). After
that, we identified 6 polymorphisms, 3 in the IL33 region (rs3939286 (C___2762168_10),
rs7025417 (C__31940410_20) and rs7044343 (C__29340326_10), located in different haplo-
type blocks of this locus, and 3 in the IL1RL1 region (rs2058660 (C__11487892_10), rs2310173
(C___2676437_10) and rs13015714 (C__31439507_10). Although these polymorphisms seem
to be apparently non-coding variants, they map and tag both IL33 and IL1RL1 regions. Regard-
ing IL33 region, rs7025417 and rs7044343 are located within IL33 gene (specifically in the pro-
moter and in the intron 5, respectively) (data in S1 fig). By contrast, rs3939286 is situated in an
intergenic region close to IL33 gene (data in S1 fig). With respect to IL1RL1 region, whereas
rs13015714 is downstream of IL1RL1 gene, both r2058660 and rs2310173 are placed close to
IL1RL1 gene (data in S2 fig).
All genetic variants were genotyped with TaqMan predesigned single nucleotide polymor-
phism genotyping assays in a 7900 HT Real-Time polymerase chain reaction (PCR) system,
IL33 and cIMT in RA
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according to the conditions recommended by the manufacturer (Applied Biosystems, Foster
City, CA, USA).
Negative controls and duplicate samples were included to check the accuracy of genotyping.
2.3. Carotid US Examination
The measurement of the cIMT was performed by carotid US. Patients from Santander were
assessed using a commercially available scanner, Mylab 70, Esaote (Genoa, Italy) equipped
with 7–12 MHz linear transducer and the automated software guided technique radiofre-
quency—Quality Intima Media Thickness in real-time (QIMT, Esaote, Maastricht, Holland)—
[16]. Patients from Lugo were assessed using high-resolution B-mode ultrasound, Hewlett
Packard SONOS 5500, with a 10-MHz linear transducer as previously reported [17]. cIMT was
measured at the far wall of the right and left common carotid arteries, 10 mm from the carotid
bifurcation, over the proximal 15 mm-long segment. cIMT was determined as the average of
three measurements in each common carotid artery. The final cIMT was the largest average
cIMT (left or right). Agreement between the two US methods in patients with RA was
Table 1. Demographic and clinical characteristics of the Spanish patients with RA included in the
study.
Clinical Features % (n/N)
Patients 576
Main characteristics
Age at the time of disease onset (years, mean ± SD) 52 ± 14.4
Follow-up (years, mean ± SD) 8.8 ± 7.1
Percentage of women 76.6
Rheumatoid factor positive* 59.6 (335/562)
Anti-CCP antibodies positive 49.9 (252/505)
Shared epitope positive 62.9 (187/297)
Erosions 39.3 (220/560)
Extra-articular manifestations** 21.4 (120/560)
Cardiovascular risk factors
Hypertension 25.3 (142/561)
Diabetes mellitus 7.1 (40/561)
Dyslipidemia 17.8 (100/561)
Obesity 9.9 (56/561)
Smoking habit 30.6 (172/561)
Patients with cardiovascular events*** 12.8 (74/576)
Ischemic heart disease 4.2 (24/576)
Heart failure 3.8 (22/576)
Cerebrovascular accident 3.3 (19/576)
Peripheral arteriopathy 1.7 (10/576)
RA: Rheumatoid arthritis; SD: Standard deviation; Anti-CCP antibodies: Anti-cyclic citrullinated peptide
antibodies.
*At least two determinations were required for analysis of this result.
** Extra-articular manifestations of the disease (if RA patients experienced at least one of the following
manifestations: nodular disease, Felty’s syndrome, pulmonary ﬁbrosis, rheumatoid vasculitis, or secondary
Sjögren’s syndrome) [2].
***At the time of assessment.
doi:10.1371/journal.pone.0143153.t001
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previously reported [18]. Experts with high experience and close collaboration in the assess-
ment of subclinical atherosclerosis in RA from Lugo and Santander performed the studies.
2.4. Statistical Analysis
All genotype data were checked for deviation from Hardy-Weinberg equilibrium (HWE) using
http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
cIMT values were displayed as mean ± standard deviation (SD). The association between
genotypes and alleles frequencies of the IL33 rs3939286, IL33 rs7025417, IL33 rs7044343,
IL1RL1 rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714 polymorphisms and cIMT val-
ues was tested using unpaired t test to compare between 2 groups and one-way analysis of vari-
ance (ANOVA) to compare among more than two groups. Comparisons of means were
adjusted for sex, age at the time of US study, follow-up time and center as potential confound-
ers using analysis of covariance (ANCOVA). Statistical significance was defined as p<0.05. All
analyses were performed with STATA statistical software 12/SE (Stata Corp., College Station,
TX, USA).
Results
All genotype distributions were in Hardy-Weinberg equilibrium. The genotyping success was
greater than 97% in all the cases.
Results of the comparisons between IL33 rs3939286, IL33 rs7025417, IL33 rs7044343,
IL1RL1 rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714 according to cIMT values are
shown in Table 2. RA patients carrying the TT genotype of the IL33 rs3939286 polymorphism
had lower cIMT values than those homozygous for the CC genotype (mean ± SD: 0.71 ± 0.14
mm versus 0.76 ± 0.16 mm, respectively) whereas patients carrying the CT genotype had inter-
mediate cIMT values (mean ± SD: 0.73 ± 0.17 mm) (Table 2). Moreover, RA patients carrying
the mutant allele T of the IL33 rs3939286 polymorphism exhibited significantly lower cIMT
values than those carrying the wild allele C (mean ± SD: 0.72 ± 0.16 mm versus 0.75 ± 0.18 mm
respectively; p = 0.04) (Table 2).
Since sex, age at the time of US study, follow-up time and center may act as potential con-
founders of the results derived from the US assessment; adjustment for these potential con-
founders was performed by an ANCOVAmodel. Interestingly, even after adjustment for
potential confounders, both genotype and allele frequencies of the IL33 rs3939286 polymor-
phism were statistically significant (p = 0.006 and p = 0.0023, respectively) evidencing that the
potential effect conferred by IL33 rs3939286 polymorphism may be independent of con-
founder factors (Table 2). Nevertheless, no significant association between IL33 rs7025417,
IL33 rs7044343, IL1RL1 rs2058660, IL1RL1 rs2310173 and IL1RL1 rs13015714 and cIMT val-
ues was observed (Table 2).
Discussion
CV disease is the most common cause of premature mortality in patients with RA being a con-
sequence of accelerated atherosclerosis [1]. In the last years, several studies have been focused
on the assessment of biologic mechanisms that influence the risk of CV disease in RA. Accord-
ingly, several genetic markers associated with the risk of subclinical atherosclerosis and CV dis-
ease in RA have recently been identified [2,4–5].
Outside the HLA region, cytokine pathway genes, which have critical modulatory effects on
innate and adaptive immunity, have been shown to represent a key component of the genetic
network associated with immune-mediated processes.
IL33 and cIMT in RA
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IL-33-IL-1RL1 pathway is a key proinflammatory mediator that may play a pathogenic role
in RA [8]. Moreover, detectable IL-33 plasma concentrations at the time of disease diagnosis
were found to predict the presence of severe subclinical atherosclerosis in the extended follow-
up of patients with RA [9]. Taking into account these considerations and the implication of 6
genetic IL33-IL1RL1 variants in the susceptibility to several inflammatory diseases [10–14], we
aimed to determine the potential association of these genetic polymorphisms with subclinical
atherosclerosis in RA. Interestingly, our results suggest a potential protection effect of the
mutant IL33 rs3939286T allele in the risk of subclinical atherosclerosis, established by the
assessment of cIMT, in patients with RA. This association remained statistically significant
after adjustment for potential confounders, evidencing that this potential effect may be inde-
pendent of sex, age at the time of the carotid US study, follow-up time and center. It is worth
noting that according to the public database RegulomeDB the IL33 rs3939286 genetic variant
appears to be a regulatory DNA element [19]. Consequently, it could be plausible to think that
the mutant IL33 rs3939286T allele might influence the development of subclinical atheroscle-
rosis by regulating the expression of IL33 and, at last, by decreasing IL-33 levels. Despite having
a cohort that might be considered relatively small, our study encompassed the largest series of
RA patients with cIMT data ever assessed for genetic studies.
In keeping with our findings, recent studies have described a protective effect of the mutant
allele of another IL33 gene polymorphism, rs7025417, in the risk of CAD in a Chinese popula-
tion and also in the development of giant cell arteritis in Europeans [11,20]. Since IL33
rs3939286 and IL33 rs7025417 genetic variants are located in different haplotype blocks and
present a low linkage disequilibrium (LD) (D´ = 0.13 and r2 = 0.01), we speculate that either
they are independent susceptibility factors for the different phenotypes or they might be tag-
ging the real causal variant.
Table 2. Association between IL33-IL1RL1 polymorphisms and cIMT values in RA patients.
IL33 SNP Genotype/Allele cIMT mm p P* IL1RL1 SNP Genotype/Allele cIMT mm p P*
mean ± SD (n) mean ± SD (n)
rs3939286 CC 0.76 ± 0.16 (258) 0.10 0.006 rs2058660 AA 0.74 ± 0.17 (325) 0.91 0.58
CT 0.73 ± 0.17 (259) AG 0.73 ± 0.18 (213)
TT 0.71 ± 0.14 (50) GG 0.75 ± 0.16 (36)
C 0.75 ± 0.18 (775) 0.04 0.0023 A 0.74 ± 0.17 (863) 0.95 0.40
T 0.72 ± 0.16 (359) G 0.74 ± 0.18 (285)
rs7025417 TT 0.75 ± 0.18 (372) 0.15 0.16 rs2310173 GG 0.74 ± 0.17 (154) 0.93 0.76
TC 0.72 ± 0.17 (172) GT 0.74 ± 0.18 (280)
CC 0.76 ± 0.20 (21) TT 0.74 ± 0.18 (142)
T 0.74 ± 0.18 (916) 0.23 0.16 G 0.74 ± 0.17 (588) 0.77 0.45
C 0.73 ± 0.17 (214) T 0.74 ± 0.18 (564)
rs7044343 TT 0.73 ± 0.17 (280) 0.35 0.33 rs13015714 TT 0.74 ± 0.18 (322) 0.88 0.39
TC 0.74 ± 0.17 (229) TG 0.73 ± 0.18 (215)
CC 0.77 ± 0.20 (54) GG 0.74 ± 0.17 (37)
T 0.73 ± 0.17 (789) 0.20 0.26 T 0.74 ± 0.18 (859) 0.73 0.29
C 0.75 ± 0.18 (337) G 0.73 ± 0.18 (289)
cIMT: carotid intima-media thickness; RA: Rheumatoid arthritis; SNP: Single nucleotide polymorphism; SD: Standard deviation. Signiﬁcant results are
highlighted on bold.
*p-value after adjusting for sex, age at the time of ultrasonography study, follow-up time and center.
doi:10.1371/journal.pone.0143153.t002
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The results obtained in the present study provide additional evidence on the potential role
that genetic factors may play in the development of CV disease in RA. The search for genetic
markers associated with CV disease in RA may be important for a better characterization of
RA patients at risk of CV disease. They may be useful to predict disease outcome at diagnosis
of RA and to establish future therapeutic targets to decrease the risk of CV disease in RA
patients.
In conclusion, our results may suggest a potential protective effect of the IL33 rs3939286
allele T in the risk of subclinical atherosclerosis in patients with RA.
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